Previous 10 | Next 10 |
Gainers: Charles & Colvard (NASDAQ: CTHR ) +34% . Buckeye Partners (NYSE: BPL ) +28% . Cardlytics (NASDAQ: CDLX ) +26% . G1 Therapeutics (NASDAQ: GTHX ) +24% . Westport Fuel Systems (NASDAQ: WPRT ) +21% . Cool Holdings (NASDAQ: AWSM ) +22% . Guardant Health (NASDAQ: GH ) +...
Puma Biotechnology (NASDAQ: PBYI ) -35% on Q1 earnings . More news on: Puma Biotechnology, Inc., TransEnterix, Inc., Verastem, Inc., Stocks on the move, Read more ...
Puma Biotechnology (NASDAQ: PBYI ) Q1 results ($M): Revenues: 99.1 (+49.0%); Nerlynx sales: 45.6 (+26.7%); license revenue: 53.5 (+75.4%). More news on: Puma Biotechnology, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Puma Biotechnology (NASDAQ: PBYI ): Q1 EPS of $0.21 may not be comparable to consensus of -$0.20. Revenue of $99.1M (+49.0% Y/Y) beats by $31.85M . Shares -29.9% . Press Release More news on: Puma Biotechnology, Inc., Earnings news and commentary, Healthcare stocks news,
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2019. Unless otherwise stated, all comparisons are for the first quarter 2019 compared to the first quarter of 2018. Product revenue, net consists entir...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:00 p.m. PDT on Wednesday, May 15, at the Bank of America Merrill Lynch Health ...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 9, 2019 following release of its first quarter 2019 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1...
On April 1, Puma Biotechnology (NASDAQ: PBYI ) announced an EU/Africa partnership for their potential blockbuster drug Nerlynx (neratinib), which is currently approved in the US and EU for HER2+ breast cancer patients post-Herceptin treatment. Under the terms of the agreement, Pierre Fabre...
Puma Biotechnology (NASDAQ: PBYI ) has added two new cohort s to its open-label Phase 2 basket study, SUMMIT , evaluating lead drug NERLYNX (neratinib) in patients with EGFR- or HER2-positive solid tumors. More news on: Puma Biotechnology, Inc., Healthcare stocks news, Read mo...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...